Rho-Kinase Inhibitor

Phase 2Small molecule

NNew York Glaucoma Research Institute

Rho-Kinase Inhibitor is one of 34 small molecule programs targeting Angle-Closure Glaucoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Angle-Closure GlaucomaActive, not recruiting

GlaucomaActive, not recruiting

Angle-Closure GlaucomaPhase 2

Active, not recruiting

GlaucomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

182 competitors in Glaucoma

#DrugCompanyPhaseTrials

Lucentis

Roche

Phase 3

2 2

Namenda

AbbVie

Phase 3

2 3

Eylea

Avastin

2 5

Viagra

VViatris Specialty LLC

Phase 3

1 6

Tocopherol

MM.D. Anderson Cancer Center

Phase 3

1 7

LUMIGAN

AbbVie

Phase 3

1 8

TFC-003

KKukje Pharma

Phase 3

1 9

Prostaglandin

LLaboratoires Thea

Phase 3

1 10

T2345

LLaboratoires Thea

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Glaucoma2 trials

A Study to Assess the Effect of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Patients With Uncontrolled Advanced Glaucoma With Prior Failed Trabeculectomy or Tube Shunt

Unknown status·NNew York Glaucoma Research Institute·Phase 2·NCT02173223·10 enrolled

A Compassionate Case Study to Assess the Hypotensive Efficacy of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Glaucoma Patients With Uncontrolled Intraocular Pressure to Avoid Surgical Intervention

Unknown status·NNew York Glaucoma Research Institute·Phase 2·NCT02174991·10 enrolled

Angle-Closure Glaucoma1 trial

A Study to Assess the Effect of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Patients With Chronic Angle-closure Glaucoma

Unknown status·NNew York Glaucoma Research Institute·Phase 2·NCT02152774·10 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Rho-Kinase Inhibitor. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Rho-Kinase Inhibitor compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Rho-Kinase Inhibitor. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — New York Glaucoma Research Institute company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: NNew York Glaucoma Research Institute

Rho-Kinase Inhibitor

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Glaucoma2 trials

Angle-Closure Glaucoma1 trial

References

Drug Info

Quick Facts

Related News